S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan

Hookipa Pharma (HOOK) Competitors

$0.77
0.00 (0.00%)
(As of 03/1/2024 ET)

HOOK vs. APLM, BCTX, RPHM, RZLT, OCUP, CLNN, KZR, GANX, SCTL, and ENLV

Should you be buying Hookipa Pharma stock or one of its competitors? The main competitors of Hookipa Pharma include Apollomics (APLM), BriaCell Therapeutics (BCTX), Reneo Pharmaceuticals (RPHM), Rezolute (RZLT), Ocuphire Pharma (OCUP), Clene (CLNN), Kezar Life Sciences (KZR), Gain Therapeutics (GANX), Societal CDMO (SCTL), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical preparations" industry.

Hookipa Pharma vs.

Hookipa Pharma (NASDAQ:HOOK) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, community ranking, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Apollomics has a net margin of 0.00% compared to Hookipa Pharma's net margin of -336.12%. Apollomics' return on equity of 0.00% beat Hookipa Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Hookipa Pharma-336.12% -70.24% -40.12%
Apollomics N/A N/A N/A

Hookipa Pharma has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Apollomics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

83.0% of Hookipa Pharma shares are held by institutional investors. Comparatively, 1.6% of Apollomics shares are held by institutional investors. 5.8% of Hookipa Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Hookipa Pharma received 80 more outperform votes than Apollomics when rated by MarketBeat users. Likewise, 68.33% of users gave Hookipa Pharma an outperform vote while only 66.67% of users gave Apollomics an outperform vote.

CompanyUnderperformOutperform
Hookipa PharmaOutperform Votes
82
68.33%
Underperform Votes
38
31.67%
ApollomicsOutperform Votes
2
66.67%
Underperform Votes
1
33.33%

Hookipa Pharma has higher revenue and earnings than Apollomics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hookipa Pharma$20.55M3.15-$64.92M-$0.83-0.93
Apollomics$1.45M45.50-$240.81MN/AN/A

Hookipa Pharma presently has a consensus price target of $5.17, indicating a potential upside of 570.91%. Apollomics has a consensus price target of $17.00, indicating a potential upside of 2,136.84%. Given Apollomics' higher possible upside, analysts clearly believe Apollomics is more favorable than Hookipa Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hookipa Pharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Apollomics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Hookipa Pharma had 2 more articles in the media than Apollomics. MarketBeat recorded 5 mentions for Hookipa Pharma and 3 mentions for Apollomics. Apollomics' average media sentiment score of 1.28 beat Hookipa Pharma's score of 0.71 indicating that Apollomics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hookipa Pharma
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Apollomics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Hookipa Pharma beats Apollomics on 8 of the 15 factors compared between the two stocks.


Get Hookipa Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HOOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HOOK vs. The Competition

MetricHookipa PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$64.65M$7.03B$5.09B$7.62B
Dividend YieldN/A2.85%2.82%3.87%
P/E Ratio-0.9313.80221.9117.05
Price / Sales3.15452.363,097.17108.91
Price / CashN/A19.4999.9255.44
Price / Book0.414.704.534.54
Net Income-$64.92M$164.41M$114.85M$211.55M
7 Day Performance20.31%7.69%5.73%3.36%
1 Month Performance13.25%15.29%12.81%6.70%
1 Year Performance-13.37%8.54%12.92%7.44%

Hookipa Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APLM
Apollomics
3.058 of 5 stars
$0.65
+4.8%
$17.00
+2,511.4%
N/A$56.51M$1.45M0.0043Short Interest ↓
News Coverage
Positive News
BCTX
BriaCell Therapeutics
2.1293 of 5 stars
$3.42
+5.9%
$18.00
+426.3%
-51.5%$54.65MN/A-1.9716Short Interest ↓
RPHM
Reneo Pharmaceuticals
3.4986 of 5 stars
$1.64
-0.6%
$18.14
+1,005.9%
-61.9%$54.63MN/A-0.6955Positive News
Gap Down
RZLT
Rezolute
3.4195 of 5 stars
$1.45
+7.4%
$8.67
+497.7%
-28.6%$57.45MN/A-1.3250Positive News
High Trading Volume
OCUP
Ocuphire Pharma
1.759 of 5 stars
$2.58
-1.9%
$18.50
+617.1%
-28.9%$58.41M$39.85M1.979Positive News
CLNN
Clene
2.0553 of 5 stars
$0.46
flat
$7.80
+1,592.0%
-66.8%$59.20M$470,000.00-1.0075News Coverage
Gap Up
KZR
Kezar Life Sciences
4.3783 of 5 stars
$0.83
-1.2%
$11.00
+1,230.8%
-81.0%$60.09MN/A-0.6884
GANX
Gain Therapeutics
2.4499 of 5 stars
$4.67
-3.1%
$8.33
+78.4%
+20.0%$60.29M$140,000.00-2.5828Short Interest ↑
Positive News
SCTL
Societal CDMO
2.6459 of 5 stars
$0.49
-2.0%
$1.88
+282.7%
-14.7%$51.35M$91.20M-1.63275Upcoming Earnings
Analyst Report
Short Interest ↓
News Coverage
ENLV
Enlivex Therapeutics
2.7786 of 5 stars
$3.27
-1.5%
$12.00
+267.0%
-18.1%$60.72MN/A-2.2250Short Interest ↓

Related Companies and Tools

This page (NASDAQ:HOOK) was last updated on 3/3/2024 by MarketBeat.com Staff